News Updates

More Articles Back to Article

GSK touts data on investigational 5-in-1 meningococcal vaccine

GSK reported that data from its Phase 3 trial evaluating MenABCWY, its five-in-one meningococcal vaccine, showed the candidate met all of the study's primary endpoints, was well tolerated and had a safety profile similar to Bexsero, or MenB, and Menveo, or MenACWY. GSK's MenABCWY, if approved, could offer the best protection against invasive meningococcal disease as it combines those two other meningococcal vaccines' antigenic components that may result in increased vaccine uptake. PMLive (UK) (3/14)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!